mmatory properties. Cell Metab 6: 137�?43.20. Odegaard JI, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116�?120.21. Matsusue K, et al. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab 7:302�?11.22. Nishino N, et al. FSP27 contributes A-674563 552325-73-2 to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J Clin Invest 118: 2808�?821.23. Tamura Y, et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 28:2195�?201.24. Yang SJ, Iglayreger HB, Kadouh HC, Bodary PF Inhibition of the chemokine ligand 2/chemokine receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy.
Diabetologia 52:972�?81.25. Barber DF, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in ADX-47273 mGluR antagonists and agonists a mouse model of systemic lupus. Nat Med 11:933�?35.26. Guillermet-Guibert J, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 105:8292�?297.27. Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11:936�?43.28. Weisberg SP, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115�?24.29. Huber J, et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity.
J Clin Endocrinol Metab 93:3215�?221.30. Nara N, et al. Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J Biol Chem 282:30794�?0803.31. Ferguson GJ, et al. PI Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol 9:86�?1.32. Nishio M, et al. Control of cell polarity and motility by the PtdIns P3 phosphatase SHIP1. Nat Cell Biol 9:36�?4.33. Nugent C, Younossi ZM Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 4:432�?41.34. Rückle T, Schwarz MK, Rommel C PI3Kgamma inhibition: Towards an aspirin of the 21st century? Nat Rev Drug Discov 5:903�?18.35.
Marone R, Cmiljanovic V, Giese B, Wymann MP Targeting phosphoinositide 3-kinase: Moving towards therapy. Biochim Biophys Acta 1784:159�?85.36. Chang JD, et al. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc Natl Acad Sci USA 104:8077�?082.37. Kubota N, et al. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 8:49�?4.38. Ueki K, et al. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 99:419�?24.39. Goyama S, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3:207�?20.40. Ito A, et al. Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue.
J Biol Chem 283: 35715�?5723.5758 | pnas/cgi/doi/10.1073/pnas.1016430108 Kobayashi et al. Isoform-Specific Functions of Phosphoinositide 3-Kinases: p110δ but Not p110γ Promotes Optimal Allergic Responses In Vivo1 Khaled Ali*, Montserrat Camps�? Wayne P. Pearce*, Hong Ji�? Thomas Rückle�? Nicolas Kuehn§, Christian Pasquali�? Christian Chabert�? Christian Rommel2,�? and Bart Vanhaesebroeck3,* *Centre for Cell Signalling, Insti